DAE9D154-5E0C-4961-9110-9E5653AAA787
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.848883048620236
- age_years
- 59
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.654
- MYC_TARGETS_V1+0.645
- E2F_TARGETS+0.588
- G2M_CHECKPOINT+0.569
- OXIDATIVE_PHOSPHORYLATION+0.539
- DNA_REPAIR+0.532
- UNFOLDED_PROTEIN_RESPONSE+0.500
- MTORC1_SIGNALING+0.462
- PROTEIN_SECRETION+0.363
- NOTCH_SIGNALING+0.333
Top 10 suppressed
- KRAS_SIGNALING_DN-0.464
- APICAL_SURFACE-0.291
- BILE_ACID_METABOLISM-0.278
- PANCREAS_BETA_CELLS-0.182
- SPERMATOGENESIS-0.179
- ESTROGEN_RESPONSE_LATE-0.156
- MYOGENESIS-0.145
- APICAL_JUNCTION-0.122
- UV_RESPONSE_DN-0.103
- ESTROGEN_RESPONSE_EARLY-0.088
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C8E7072F-6FBB-4BF8-8917-0C0CBDAF7605 | — | — | 0.960 |
| 2 | 23F34B20-F029-44F5-B3B5-06A74FC0FC9D | — | — | 0.955 |
| 3 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.952 |
| 4 | ECCC2F18-409F-41BA-B49F-95B23893B80B | — | — | 0.942 |
| 5 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.931 |
| 6 | 8F828A42-3E60-40C1-9E7D-428ABEA6C72F | — | — | 0.931 |
| 7 | 58A2E073-D3DE-44B2-9065-3DE14B53B3A2 | — | — | 0.930 |
| 8 | AA605CB6-ABD9-4802-8784-75A18A74C87B | — | — | 0.927 |
| 9 | SRR934817 | — | — | 0.922 |
| 10 | 4FE5EDE2-7790-4A75-9BB6-93260A8154A0 | — | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.654 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.645 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.588 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.569 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.539 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.532 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.500 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.462 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.363 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.333 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.331 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.319 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.316 | Inavolisib | — uncovered |
| APOPTOSIS | 0.299 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.282 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.279 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.279 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.271 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.248 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.227 | Inavolisib | — uncovered |